Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Advanced Or Metastatic Solid Tumors
• Age: Between 18 years - 99 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Phase 1: Subjects with advanced or metastatic HNSCC, NSCLC, ovarian, PD-L1 low (TPS <50%) expressing malignancies, cervical cancer, endometrial cancer, gastric cancer (including stomach, esophageal, and gastroesophageal junction), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) colorectal cancer (CRC), renal cell carcinoma (RCC), triple negative breast cancer (TNBC), and urothelial carcinoma. 2) Phase 2: Subjects with advanced or metastatic HNSCC, NSCLC, ovarian, and PD-L1 low (TPS <50%) expressing malignancies.
  

You may not be eligible for this study if the following are true:

• 1) Has not recovered to = Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy. 2) Receipt of a live vaccine within 30 days of planned start of study therapy. 3) Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Subjects who have not required systemic treatment in the past 2 years may be eligible with approval of the medical monitor.